We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01703234
First Posted: October 10, 2012
Last Update Posted: October 10, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Mahmut Ilker Yilmaz, Gulhane School of Medicine
  Purpose
There is no data about the effects of Renin angiotensin system blockage (RAS) on FGF23 and ADMA levels in diabetic patients with proteinuria. The aim of this study was to find out whether the beneficial effects of RAS blockage in diabetic proteinuria has any relation with the alteration of ADMA and FGF-23 levels. We searched for the effects of ACE inhibitor ramipril on the clinical and laboratory parameters of diabetic patients with proteinuria.

Condition Intervention Phase
Proteinuria Diabetic Nephropathy Chronic Kidney Disease Drug: Ramipril Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Mahmut Ilker Yilmaz, Gulhane School of Medicine:

Primary Outcome Measures:
  • Flow Mediated Dilatation

Secondary Outcome Measures:
  • FGF-23

Enrollment: 78
Study Start Date: January 2008
Study Completion Date: April 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ramipril Drug: Ramipril
ramipril 10 mg/day during 3 months

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • CKD stage 1 patients
  • Older than 18 years of age
  • Type 2 Diabetic patients
  • Proteinuria

Exclusion Criteria:

  • History of coronary artery disease
  • Smokers
  • Taking statins or renin-angiotensin blockers
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01703234


Locations
Turkey
Gulhane School of Medicine
Ankara, Turkey
Sponsors and Collaborators
Gulhane School of Medicine
  More Information

Responsible Party: Mahmut Ilker Yilmaz, Assoc.Prof., Gulhane School of Medicine
ClinicalTrials.gov Identifier: NCT01703234     History of Changes
Other Study ID Numbers: GATARAMFGF232012
First Submitted: October 4, 2012
First Posted: October 10, 2012
Last Update Posted: October 10, 2012
Last Verified: October 2012

Keywords provided by Mahmut Ilker Yilmaz, Gulhane School of Medicine:
FGF-23 , ramipril, endothelial dysfunction

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Diabetic Nephropathies
Proteinuria
Urologic Diseases
Renal Insufficiency
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Urination Disorders
Urological Manifestations
Signs and Symptoms
Ramipril
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents